Computable Genomix qPCR

Bioinformatic GeneIndexer latent semantic indexing (LSI) plasmids

computablegenomix
Ae1 Ae3 Antibody Antibodies Assay Kits Bafilomycin A1 Bile Acid Assay Biology Cells Canine Albumin cDNA Choline Acetyltransferase Antibody Clia Kits Culture Cells Deoxycholic Acid Sodium Salt Devices DNA DNA Templates DNA Testing Enzymes Equipments Exosomes F Actin Antibody Fto Antibody Gels Glycodeoxycholic Acid Gsk3 Alpha Hama Antibodies Hdac Activity Assay Isotypes Laminin Alpha 5 Medium & Serums Mip 1B Mmp Activity Assay Mothers Against Decapentaplegic Mouse Albumin Elisa Panel Particles PCR Pcr Kits Pepstatin A Peptides Phospho 4Ebp1 Primary Antibodies Reagents Recombinant Proteins Tgf Alpha Elisa Trypsin Activity Assay Tubastatin A Uric Acid Assay Valproic Acid Sodium Salt Vector & Virus

An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients

Background & intention: We investigated the mixture of speedy antigen detection (RAD) and RT-qPCR assays in a stepwise process to optimize the detection of COVID-19.
Strategies: From August 2020 to November 2020, 43,399 sufferers had been screened in our laboratory for COVID-19 diagnostic by RT-qPCR utilizing nasopharyngeal swab. General, 4,691 of the 43,399 had been discovered to be optimistic, and 200 had been retrieved for RAD testing permitting comparability of diagnostic accuracy between RAD and RT-qPCR. Cycle threshold (Ct) and time from signs onset (TSO) had been included as covariates.
Outcomes: The general sensitivity, specificity, PPV, NPV, LR-, and LR+ of RAD in contrast with RT-qPCR had been 72% (95%CI 62%-81%), 99% (95% CI95%-100%), 99% (95%CI 93%-100%), and 78% (95%CI 70%-85%), 0.28 (95%CI 0.21-0.39), and 72 (95%CI 10-208) respectively. Sensitivity was increased for sufferers with Ct ≤ 25 no matter TSO: TSO ≤ Four days 92% (95%CI 75%-99%), TSO > Four days 100% (95%CI 54%-100%), and asymptomatic 100% (95%CI 78-100%). General, combining RAD and RT-qPCR would enable lowering from solely 4% the variety of RT-qPCR wanted.
Conclusions: This research highlights the chance of misdiagnosing COVID-19 in 28% of sufferers if RAD is used alone. A stepwise evaluation that mixes RAD and RT-qPCR can be an environment friendly screening process for COVID-19 detection and will facilitate the management of the outbreak.

 

On the lookout for extra dependable biomarkers in breast most cancers: Comparability between routine strategies and RT-qPCR

Objective: A long time of high quality management efforts have raised the requirements of immunohistochemistry (IHC), the precept methodology used for biomarker testing in breast most cancers; nonetheless, computational pathology and reverse transcription quantitative PCR (RT-qPCR) may maintain promise for added substantial enhancements.
Strategies: Herein, we investigated discrepancies within the evaluation of estrogen receptor (ER), progesterone receptor (PR), human epidermal progress issue receptor 2 (HER2) and marker of proliferation Ki67 evaluating routinely obtained IHC (and FISH) knowledge (ORI) with the outcomes of handbook (REV) and semi-automated (DIA) re-evaluation of the unique IHC slides after which with RNA expression knowledge from the identical tissue block utilizing the MammaTyper® (MT) gene expression assay.
Outcomes: Correlation for ER and PR was excessive between ORI IHC and the opposite three research strategies (REV, DIA and RT-qPCR). For HER2, 10 out of 96 discrepant instances could be detected between ORI and REV that concerned a minimum of one name within the equivocal class (apart from one case). For Ki67, 22 (29.1%) instances had been categorized in a different way by both REV alone (n = 17), DIA alone (n = 15) or each (n = 10) and 28 instances (29.2%) for RT-qPCR. A lot of the discrepant Ki67 instances modified from low to excessive between the unique and following evaluation and belonged to the intermediate Ki67 expression vary (between 9 and 30%).
Conclusions: Dedication of the breast most cancers biomarkers ER, PR, HER2 and Ki67 on the mRNA degree reveals excessive diploma of correlation with IHC and compares nicely with correlations between authentic with subsequent unbiased handbook or semi-automated IHC assessments. The usage of strategies with wider dynamic vary and better reproducibility similar to RT-qPCR could provide extra exact evaluation of endocrine responsiveness, enhance Ki67 standardization and assist resolve HER2 instances that stay equivocal or ambiguous by IHC/FISH. In abstract, our findings appear to configure RT-qPCR as a complementary methodology for use in instances of both equivocal outcomes or presenting, on the conventional dedication assays, biomarkers expressions near the cut-off values.
computablegenomix
computablegenomix

Utility of Repeat Nasopharyngeal SARS-CoV-2 RT-PCR Testing and Refinement of Diagnostic Stewardship Strategies at a Tertiary Care Tutorial Center in a Low-Prevalence House of america

Background: Quite a few parts have led to a very extreme amount of maximum acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription polymerase chain response (RT-PCR) testing. Concerns exist about sensitivity and false-negative SARS-CoV-2 RT-PCR testing outcomes. We describe a retrospective observational analysis inspecting the utility of repeat nasopharyngeal (NP) SARS-CoV-2 RT-PCR testing at a tutorial coronary heart in a low-prevalence setting.

Methods: All victims inside our nicely being system with >1 NP SARS-CoV-2 RT-PCR examine end result have been included. SARS-CoV-2 RT-PCR testing was carried out based mostly on 1 of 4 validated assays. Key scientific and demographic info have been collected, along with whether or not or not the affected individual was inpatient or outpatient at time of the examine and whether or not or not the examine was carried out as part of a person under investigation (PUI) for potential coronavirus sickness 2019 or for asymptomatic screening.

 

Outcomes: An entire of 660 victims had >1 NP SARS-CoV-2 PCR examine carried out. The preliminary examine was unfavourable in 638. There have been solely 6 negative-to-positive conversions (0.9%). All 6 have been outpatients current course of a PUI workup 5-17 days after an preliminary unfavourable end result. In >260 inpatients with repeat testing, we found no instances of negative-to-positive conversion along with these current course of PUI or asymptomatic evaluation.

Conclusions: In a low-prevalence house, repeat inpatient testing after an preliminary unfavourable end result, using a extraordinarily analytically delicate SARS-CoV-2 RT-PCR, did not present negative-to-positive conversion. The scientific sensitivity of NP RT-PCR testing may be larger than beforehand believed. These outcomes have helped kind diagnostic stewardship pointers, significantly steering to decrease repeated testing inside the inpatient setting to optimize examine utilization and defend belongings.

 

Enchancment of a real-time PCR assay for detection and quantification of Streptococcus iniae using the lactate permease gene

The aim of this analysis is the occasion and evaluation of a quick and proper quantitative PCR (qPCR)-based protocol for detection of zoonotic pathogen Streptococcus iniae in bacterial cultures and tissues of diseased fish. For this purpose, the lactate permease-encoding (lldY) gene was chosen as a purpose for the design of S. iniae-specific primers based on comparative genomic analysis using 45 sequences retrieved from NCBI genome database. Specificity and applicability of these primers have been examined using 115 bacterial strains and fish tissues contaminated with S. iniae.

Sensitivity, reproducibility and effectivity of qPCR assay have been moreover determined. The developed qPCR assay confirmed 100% specificity with pure bacterial cultures or DNA extracted from S. iniae or tissues of fish contaminated with the bacterium. The technique has extreme sensitivity with a detection limit of 1.12 × 101 amplicon copies per assay (equal to 2 × 10-9 ng/µl) using bacterial DNA and of 1.44 × 101 gene copies in tissues of fish contaminated with S. iniae. In conclusion, this qPCR protocol provides an appropriate and delicate varied for the identification of S. iniae and its detection on fish tissues which may be carried out as a routine instrument in microbiological laboratories.

 

Enchancment of a New Multiplex Precise Time RT-PCR Assay for SARS-CoV-2 Detection

We describe the occasion of a model new multiplex precise time reverse transcription (RT)-PCR examine for detection of SARS-CoV-2, with primers designed to amplify a 108 bp purpose on the spike ground glycoprotein (S gene) and a hydrolysis Taqman probe designed to significantly detect SARS-CoV-2. We then evaluated the limit of detection (LOD) and scientific effectivity of this new assay. A LOD analysis with inactivated virus exhibited equal effectivity to the modified CDC assay with a closing LOD of 1,301 ± 13 genome equivalents/ml for the Northwell Nicely being Laboratories laboratory developed examine (NWHL LDT) vs. 1,249 ± 14 genome equivalents/ml for the modified CDC assay.

 

Furthermore, a scientific evaluation with 270 nasopharyngeal (NP) swab specimens exhibited 98.5% optimistic % settlement and 99.3% unfavourable % settlement compared with the modified CDC assay. The NWHL LDT multiplex design permits testing of 91 victims per plate, versus a most of 29 victims per plate on the modified CDC assay, providing the benefit of testing significantly further victims per run and saving reagents, all through a time when every of these parameters are essential.

 

The outcomes present that the NWHL LDT multiplex assay performs along with the modified CDC assay, nonetheless is further setting pleasant and worth environment friendly and could be utilized as a diagnostic assay and for epidemiological surveillance and scientific administration of SARS-CoV-2.

 

GPR160 Antibody

MBS7119398-005mg 0.05mg
EUR 150

GPR160 Antibody

MBS7119398-01mg 0.1mg
EUR 190

GPR160 Antibody

MBS7119398-5x01mg 5x0.1mg
EUR 845

GPR160 antibody

70R-50939 100 ul
EUR 242
Description: Purified Polyclonal GPR160 antibody

GPR160 antibody

70R-31407 100 ug
EUR 294
Description: Rabbit polyclonal GPR160 antibody

GPR160 Antibody

E11-140G 100μg
EUR 225
Description: Available in various conjugation types.

GPR160 Antibody

E19-4899 100μg/100μl
EUR 225
Description: Available in various conjugation types.

GPR160 Antibody

E047605 100μg/100μl
EUR 255
Description: Available in various conjugation types.

GPR160 Antibody

47605 100ul
EUR 319

GPR160 Antibody

47605-100ul 100ul
EUR 302.4

GPR160 Antibody

ABD4899 100 ug
EUR 525.6

GPR160 Antibody

DF4899 200ul
EUR 420

GPR160 Antibody

DF4899-100ul 100ul
EUR 168
Description: WB,IF/ICC,ELISA(peptide)

GPR160 Antibody

DF4899-200ul 200ul
EUR 210
Description: WB,IF/ICC,ELISA(peptide)

GPR160 Antibody

1-CSB-PA008825
  • Ask for price
  • Ask for price
  • 50ug
  • 100ug
Description: A polyclonal antibody against GPR160. Recognizes GPR160 from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/10000

GPR160 Antibody

G140-100ul 100μl
EUR 217
Description: GPR160 Rabbit Polyclonal Antibody

GPR160 Antibody

G140-50ul 50μl
EUR 143.5
Description: GPR160 Rabbit Polyclonal Antibody

GPR160 antibody

MBS535434-005mg 0.05mg
EUR 1125

GPR160 antibody

MBS535434-5x005mg 5x0.05mg
EUR 4905

GPR160 Antibody

MBS5315557-01mL 0.1mL
EUR 470

GPR160 Antibody

MBS5315557-5x01mL 5x0.1mL
EUR 1955

GPR160 Antibody

MBS8515601-01mg 0.1mg
EUR 305

GPR160 Antibody

MBS8515601-01mLAF405L 0.1mL(AF405L)
EUR 465

GPR160 Antibody

MBS8515601-01mLAF405S 0.1mL(AF405S)
EUR 465

GPR160 Antibody

MBS8515601-01mLAF610 0.1mL(AF610)
EUR 465

GPR160 Antibody

MBS8515601-01mLAF635 0.1mL(AF635)
EUR 465

GPR160 Antibody

MBS853183-01mg 0.1mg
EUR 305

GPR160 Antibody

MBS853183-01mLAF405L 0.1mL(AF405L)
EUR 465

GPR160 Antibody

MBS853183-01mLAF405S 0.1mL(AF405S)
EUR 465

GPR160 Antibody

MBS853183-01mLAF610 0.1mL(AF610)
EUR 465

GPR160 Antibody

MBS853183-01mLAF635 0.1mL(AF635)
EUR 465

GPR160 Antibody

MBS9606351-01mL 0.1mL
EUR 260

GPR160 Antibody

MBS9606351-02mL 0.2mL
EUR 305

GPR160 Antibody

MBS9606351-5x02mL 5x0.2mL
EUR 1220

GPR160 Antibody

MBS9232645-01mL 0.1mL
EUR 415

GPR160 Antibody

MBS9232645-5x01mL 5x0.1mL
EUR 1841

GPR160 Antibody

MBS9430587-01mL 0.1mL
EUR 305

GPR160 Antibody

MBS9430587-5x01mL 5x0.1mL
EUR 1230

GPR160 Antibody

MBS9507949-005mL 0.05mL
EUR 285

GPR160 Antibody

MBS9507949-01mL 0.1mL
EUR 385

GPR160 Antibody

MBS9507949-5x01mL 5x0.1mL
EUR 1590

GPR160 Antibody

MBS9509528-005mL 0.05mL
EUR 285

GPR160 Antibody

MBS9509528-01mL 0.1mL
EUR 385

GPR160 Antibody

MBS9509528-5x01mL 5x0.1mL
EUR 1590

GPR160 Polyclonal Antibody

ABP54526-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of GPR160 from Human. This GPR160 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human GPR160 at AA rangle: 270-350

GPR160 Polyclonal Antibody

ABP54526-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of GPR160 from Human. This GPR160 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human GPR160 at AA rangle: 270-350

GPR160 Polyclonal Antibody

ABP54526-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of GPR160 from Human. This GPR160 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human GPR160 at AA rangle: 270-350

GPR160 Polyclonal Antibody

E20-71990 100ug
EUR 225
Description: Available in various conjugation types.

GPR160 Polyclonal Antibody

BT-AP03712-100ul 100ul Ask for price
Description: Orphan receptor.

GPR160 Polyclonal Antibody

BT-AP03712-20ul 20ul Ask for price
Description: Orphan receptor.

GPR160 Polyclonal Antibody

BT-AP03712-50ul 50ul Ask for price
Description: Orphan receptor.

GPR160 Conjugated Antibody

C47605 100ul
EUR 476.4

GPR160 Polyclonal Antibody

E-AB-19949-120uL 120uL
EUR 240
Description: Unconjugated

GPR160 Polyclonal Antibody

E-AB-19949-200uL 200uL
EUR 399
Description: Unconjugated

GPR160 Polyclonal Antibody

E-AB-19949-20uL 20uL
EUR 73
Description: Unconjugated

GPR160 Polyclonal Antibody

E-AB-19949-60uL 60uL
EUR 143
Description: Unconjugated

GPR160 Polyclonal Antibody

E44H04883 100ul
EUR 255
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

GPR160 Polyclonal Antibody

JOT-AP03712-100ul 100ul
EUR 220
Description: Human

GPR160 Polyclonal Antibody

JOT-AP03712-50ul 50ul
EUR 144
Description: Human

GPR160 Polyclonal Antibody

MBS2561838-002mL 0.02mL
EUR 135

GPR160 Polyclonal Antibody

MBS2561838-006mL 0.06mL
EUR 190

GPR160 Polyclonal Antibody

MBS2561838-012mL 0.12mL
EUR 265

GPR160 Polyclonal Antibody

MBS2561838-02mL 0.2mL
EUR 415

GPR160 Polyclonal Antibody

MBS2561838-5x02mL 5x0.2mL
EUR 1835

GPR160 Polyclonal Antibody

MBS8522971-01mg 0.1mg
EUR 305

GPR160 Polyclonal Antibody

MBS8522971-01mLAF405L 0.1mL(AF405L)
EUR 465

GPR160 Polyclonal Antibody

MBS8522971-01mLAF405S 0.1mL(AF405S)
EUR 465

GPR160 Polyclonal Antibody

MBS8522971-01mLAF610 0.1mL(AF610)
EUR 465

GPR160 Polyclonal Antibody

MBS8522971-01mLAF635 0.1mL(AF635)
EUR 465

GPR160 Conjugated Antibody

MBS9455452-01mLAF350 0.1mL(AF350)
EUR 480

GPR160 Conjugated Antibody

MBS9455452-01mLAF405 0.1mL(AF405)
EUR 480

GPR160 Conjugated Antibody

MBS9455452-01mLAF488 0.1mL(AF488)
EUR 480

GPR160 Conjugated Antibody

MBS9455452-01mLAF555 0.1mL(AF555)
EUR 480

GPR160 Conjugated Antibody

MBS9455452-01mLBiotin 0.1mL(Biotin)
EUR 480

GPR160 Polyclonal Antibody

RD219949A-120uL 120μL
EUR 360
Description: Orphan receptor.

GPR160 Polyclonal Antibody

RD219949A-200uL 200μL
EUR 630
Description: Orphan receptor.

GPR160 Polyclonal Antibody

RD219949A-20uL 20μL
EUR 109.5
Description: Orphan receptor.

GPR160 Polyclonal Antibody

RD219949A-60uL 60μL
EUR 214.5
Description: Orphan receptor.

GPR160 Polyclonal Antibody

UB-GEN-13108 100 ul
EUR 200

GPR160 Antibody (C-term)

MBS9213578-008mL 0.08mL
EUR 210

GPR160 Antibody (C-term)

MBS9213578-04mL 0.4mL
EUR 430

GPR160 Antibody (C-term)

MBS9213578-5x04mL 5x0.4mL
EUR 1910

Polyclonal GPR160 Antibody (Internal)

APR16513G 0.05ml
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR160 (Internal). This antibody is tested and proven to work in the following applications:

GPR160 Rabbit Polyclonal Antibody

E10G13515 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

GPR160 Rabbit Polyclonal Antibody

E10G06629 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

GPR160 Rabbit Polyclonal Antibody

ES5525-100ul 100ul
EUR 124
Description: WB, IHC, IF, ELISA

GPR160 Rabbit Polyclonal Antibody

ES5525-50ul 50ul
EUR 74
Description: WB, IHC, IF, ELISA

GPR160 Antibody - C-terminal region

MBS3217022-01mL 0.1mL
EUR 455

GPR160 Antibody - C-terminal region

MBS3217022-5x01mL 5x0.1mL
EUR 1995

GPR160 Antibody - N-terminal region

MBS3217023-01mL 0.1mL
EUR 455

 

Christopher Miller

Tags:
computablegenomix
computablegenomix